BioWorld Today: Clinic Roundup--MacroGenics, Inc.

May 23, 2013 - BioWorld Today

MacroGenics, Inc., of Rockville, Md., said the first patient was dosed in a Phase II study at six U.S. sites evaluating its next-generation anti-HER2 monoclonal antibody, margetuximab, in metastatic breast cancer. The study is designed to evaluate margetuximab in up to 41 patients with metastatic breast cancer whose tumors express a moderate level of HER2.